Idarubicin Injection 5 mg/5 mL (5)

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

idarubicin hydrochloride, Quantity: 1 mg/mL

Available from:

Pfizer (Perth) Pty Ltd

Pharmaceutical form:

Injection, solution

Composition:

Excipient Ingredients: glycerol; hydrochloric acid; water for injections

Administration route:

Intravenous

Units in package:

1 X 5 mL

Prescription type:

(S1) This Schedule is intentionally blank

Therapeutic indications:

Acute myeloid leukaemia in combination with other cytotoxic agents. Acute lymphoblastic leukaemia as a reserve medicinal product in combination with other cytotoxic agents.

Product summary:

Visual Identification: Plastic vials containing a red-orange, clear, mobile solution; Container Type: Vial; Container Material: PP; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Listed (Export Only)

Authorization date:

2023-03-03